Header Logo

Connection

THOMAS KOSTEN to Narcotic Antagonists

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Narcotic Antagonists.
THOMAS KOSTEN
Connection Strength
7.247
Narcotic Antagonists
  1. Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury. JAMA Psychiatry. 2018 06 01; 75(6):649-650.
    View in: PubMed
    Score: 0.537
  2. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother. 2016 Dec; 17(17):2307-2318.
    View in: PubMed
    Score: 0.480
  3. Buprenorphine Prescribing: To Expand or Not to Expand. J Psychiatr Pract. 2016 05; 22(3):183-92.
    View in: PubMed
    Score: 0.465
  4. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. Expert Opin Pharmacother. 2014 Oct; 15(15):2263-75.
    View in: PubMed
    Score: 0.414
  5. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend. 2014 Mar 01; 136:36-42.
    View in: PubMed
    Score: 0.395
  6. Pharmacotherapy for stimulant-related disorders. Curr Psychiatry Rep. 2013 Nov; 15(11):415.
    View in: PubMed
    Score: 0.391
  7. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. Drug Alcohol Depend. 2013 Oct 01; 132(3):674-80.
    View in: PubMed
    Score: 0.378
  8. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug; 10(11):1727-40.
    View in: PubMed
    Score: 0.291
  9. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse. 2008; 34(4):355-81.
    View in: PubMed
    Score: 0.261
  10. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl). 2007 Mar; 190(4):569-74.
    View in: PubMed
    Score: 0.242
  11. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004 Sep; 27(2):153-9.
    View in: PubMed
    Score: 0.207
  12. Buprenorphine for office-based practice: consensus conference overview. Am J Addict. 2004; 13 Suppl 1:S1-7.
    View in: PubMed
    Score: 0.198
  13. D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol. 2003 Aug; 11(3):237-46.
    View in: PubMed
    Score: 0.192
  14. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514.
    View in: PubMed
    Score: 0.192
  15. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse. 2003; 29(4):713-27.
    View in: PubMed
    Score: 0.184
  16. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
    View in: PubMed
    Score: 0.174
  17. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Addict Behav. 2020 12; 111:106538.
    View in: PubMed
    Score: 0.155
  18. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000 Jun 15; 47(12):1072-9.
    View in: PubMed
    Score: 0.155
  19. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999 Sep; 56(9):812-20.
    View in: PubMed
    Score: 0.146
  20. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. Am J Addict. 2019 11; 28(6):480-488.
    View in: PubMed
    Score: 0.146
  21. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend. 1998 Oct 01; 52(2):173-6.
    View in: PubMed
    Score: 0.137
  22. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug Alcohol Depend. 2018 06 01; 187:171-178.
    View in: PubMed
    Score: 0.133
  23. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998 Jan 21; 279(3):229-34.
    View in: PubMed
    Score: 0.131
  24. Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients. J Subst Abuse Treat. 1997 Mar-Apr; 14(2):149-54.
    View in: PubMed
    Score: 0.123
  25. Reliability of sequential naloxone challenge tests. Am J Drug Alcohol Abuse. 1995 Nov; 21(4):453-67.
    View in: PubMed
    Score: 0.112
  26. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse. 1995 Nov; 21(4):469-81.
    View in: PubMed
    Score: 0.112
  27. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012 May; 38(3):187-99.
    View in: PubMed
    Score: 0.087
  28. Prescription pain medication dependence. Am J Psychiatry. 2011 May; 168(5):466-71.
    View in: PubMed
    Score: 0.082
  29. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989; 44(13):887-92.
    View in: PubMed
    Score: 0.070
  30. Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict. 2008 Jul-Aug; 17(4):287-92.
    View in: PubMed
    Score: 0.068
  31. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17.
    View in: PubMed
    Score: 0.053
  32. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004 Apr; 5(4):713-25.
    View in: PubMed
    Score: 0.050
  33. Management of drug and alcohol withdrawal. N Engl J Med. 2003 May 01; 348(18):1786-95.
    View in: PubMed
    Score: 0.047
  34. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002 Jul; 1(1):13-20.
    View in: PubMed
    Score: 0.045
  35. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract. 2022 01 31; 17(1):6.
    View in: PubMed
    Score: 0.043
  36. Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs. 2002; 62(9):1331-43.
    View in: PubMed
    Score: 0.043
  37. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000 Jun 15; 47(12):1080-6.
    View in: PubMed
    Score: 0.039
  38. The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers. Biol Psychiatry. 1999 Jun 15; 45(12):1636-45.
    View in: PubMed
    Score: 0.036
  39. Buprenorphine for the treatment of posttraumatic stress disorder. Am J Addict. 2019 02; 28(2):86-91.
    View in: PubMed
    Score: 0.035
  40. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998 Aug; 105(2):100-5.
    View in: PubMed
    Score: 0.034
  41. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. J Subst Abuse Treat. 1998 May-Jun; 15(3):261-5.
    View in: PubMed
    Score: 0.033
  42. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997 Oct 01; 127(7):526-30.
    View in: PubMed
    Score: 0.032
  43. Dose dependent effects of yohimbine on methadone maintained patients. Am J Drug Alcohol Abuse. 1997 May; 23(2):327-33.
    View in: PubMed
    Score: 0.031
  44. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat. 1995 Nov-Dec; 12(6):423-8.
    View in: PubMed
    Score: 0.028
  45. Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis. 1991 Oct; 179(10):583-92.
    View in: PubMed
    Score: 0.021
  46. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001; 10(4):296-307.
    View in: PubMed
    Score: 0.010
  47. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am. 1997 Jul; 81(4):909-25.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.